Jose M Estrada-Grossmann, Esteban A Alarcón-Braga, Farley E Salazar-Valdivia, Abigail S Jauregui-Cornejo, Karlos Acurio, Niels Pacheco-Barrios, Ali Al-Kassab-Córdova, Daniel Enriquez-Vera
{"title":"Risk Factors for Malignant Progression to Adult-T-Cell Leukemia/Lymphoma in HTLV-1 Carriers: A Systematic Review of Cohort and Case-Control Studies.","authors":"Jose M Estrada-Grossmann, Esteban A Alarcón-Braga, Farley E Salazar-Valdivia, Abigail S Jauregui-Cornejo, Karlos Acurio, Niels Pacheco-Barrios, Ali Al-Kassab-Córdova, Daniel Enriquez-Vera","doi":"10.1016/j.clml.2025.04.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To systematically evaluate and synthesize the existing evidence from cohort and case-control studies to identify risk factors associated with malignant progression to ATLL in HTLV-1 carriers.</p><p><strong>Methods: </strong>A systematic search was conducted in September 2023 in the following databases: Pubmed, Scopus, Web of Science, Medline and Embase. Only case-control and cohort studies that assessed the risk factors for the malignant progression to ATLL among HTLV-1 carriers in the adult population were included. The risk of bias was assessed through the Newcastle-Ottawa Scale. Meta-analysis was not performed due to high statistical and methodological heterogeneity.</p><p><strong>Results: </strong>After conducting a systematic search, 8170 results were retrieved, of which 9 (7 case-control and 2 cohort studies) met the selection criteria. Seven of them were conducted in Japan and six had low risk of bias. Serum sIL-2R levels, proviral load (PVL), cigarette consumption, Scd30 and TNF-α-857T allele were associated with an increased risk of ATLL progression.</p><p><strong>Conclusion: </strong>PVL emerges as the foremost recommended biomarker for predicting progression in patients with HTLV-1 associated ATLL. Further studies with larger samples sizes, different populations, more rigorous statistical adjustments, and longer follow-up are warranted.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.04.013","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To systematically evaluate and synthesize the existing evidence from cohort and case-control studies to identify risk factors associated with malignant progression to ATLL in HTLV-1 carriers.
Methods: A systematic search was conducted in September 2023 in the following databases: Pubmed, Scopus, Web of Science, Medline and Embase. Only case-control and cohort studies that assessed the risk factors for the malignant progression to ATLL among HTLV-1 carriers in the adult population were included. The risk of bias was assessed through the Newcastle-Ottawa Scale. Meta-analysis was not performed due to high statistical and methodological heterogeneity.
Results: After conducting a systematic search, 8170 results were retrieved, of which 9 (7 case-control and 2 cohort studies) met the selection criteria. Seven of them were conducted in Japan and six had low risk of bias. Serum sIL-2R levels, proviral load (PVL), cigarette consumption, Scd30 and TNF-α-857T allele were associated with an increased risk of ATLL progression.
Conclusion: PVL emerges as the foremost recommended biomarker for predicting progression in patients with HTLV-1 associated ATLL. Further studies with larger samples sizes, different populations, more rigorous statistical adjustments, and longer follow-up are warranted.
目的：系统评价和综合来自队列和病例对照研究的现有证据，以确定HTLV-1携带者恶性进展为ATLL的相关危险因素。方法：于2023年9月系统检索Pubmed、Scopus、Web of Science、Medline、Embase等数据库。仅纳入了评估成人HTLV-1携带者恶性进展为ATLL危险因素的病例对照和队列研究。偏倚风险通过纽卡斯尔-渥太华量表进行评估。由于统计和方法学异质性高，未进行meta分析。结果：经系统检索，共检索到8170项结果，其中9项（7项病例对照研究和2项队列研究）符合入选标准。其中7项在日本进行，6项具有低偏倚风险。血清sIL-2R水平、前病毒载量（PVL）、吸烟、Scd30和TNF-α-857T等位基因与ATLL进展风险增加相关。结论：PVL是预测HTLV-1相关ATLL患者进展的首选生物标志物。进一步的研究需要更大的样本量、不同的人群、更严格的统计调整和更长的随访时间。
期刊介绍：
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
